Basilea Enters Global Collaboration With Johnson & Johnson Affiliate

Basilea Pharmaceutica AG has entered into an exclusive worldwide agreement with Cilag AG International, a Johnson & Johnson company, to develop, manufacture and market ceftobiprole, Basilea's novel broad-spectrum cephalosporin antibiotic that has activity against methicillin-resistant Staphylococcus aureus (MRSA). Ceftobiprole is in Phase III clinical trials in complicated skin and skin structure infections and hospital-acquired pneumonia trials are in preparation. Both indications have been granted fast-track designation by the FDA.

PrimeZone (http://www.primezone.com/newsroom/?d=72017)